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Background: DNA methylation is the most studied form of epigenetic regulation, a process by which chromatin
composition and transcription factor binding is altered to influence tissue specific gene expression and
differentiation. Such tissue specific methylation patterns are investigated as biomarkers for cancer and cell-free fetal
DNA using various methodologies.
Results: We have utilized methylation DNA immunoprecipitation (MeDIP) and real-time quantitative PCR to investigate
the inter-individual methylation variability of differentially methylated regions (DMRs) on chromosomes 18 and 21. We
have characterized 15 newly selected and seven previously validated DMRs in 50, 1st trimester Chorionic villus
samplings (CVS) and 50 female non-pregnant peripheral blood (WBF) samples. qPCR results from MeDIP and genomic
DNA (Input) assays were used to calculate fold enrichment values for each DMR. For all regions tested, enrichment was
higher in CVS than in WBF samples with mean enrichments ranging from 0.22 to 6.4 and 0.017 to 1 respectively.
Despite inter-individual variability, mean enrichment values for CVS were significantly different than those for WBF in all
DMRs tested (p < 0.01). This observation is reinforced by the absence of overlap in CVS and WBF enrichment value
distributions for 15 of 22 DMRs.
Conclusions: Our work provides an expansion in the biomarker panel available for non-invasive prenatal diagnosis
(NIPD) using the MeDIP-qPCR methology for Down syndrome and can eventually provide the starting point towards
the development for assays towards the detection of Edwards syndrome. Furthermore, our data indicate that
inter-experimental and inter-individual variation in methylation is apparent, yet the difference in methylation status
across tissues is large enough to allow for robust tissue specific methylation identification.
Keywords: Non-invasive prenatal diagnosis, Inter-individual variability, Differentially methylated regions, MeDIPBackground
In vertebrates DNA methylation is a conserved epigenetic
modification by which DNA methyltransferases add a me-
thyl group to carbon 5 of cytosine residues present in
CpG dinucleotides. This modification is the most studied
form of epigenetic regulation and has been strongly asso-
ciated with chromosomal stability and imprinting control
[1]. Furthermore, this epigenetic process also regulates
chromatin composition and transcription factor binding
to directly influence transcriptional activity [2,3].* Correspondence: patsalis@cing.ac.cy
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unless otherwise stated.DNA methylation occurs primarily in CpG islands
(GGIs) and shores both in coding and non-coding re-
gions of the genome, with gene regulatory regions such
as promoters and first exons being a frequent methyla-
tion target [4]. Due to this integral relationship with
gene expression regulation, DNA methylation patterns
are very closely associated with developmental processes
and differentiation. Consequently, DNA methylation dir-
ectly modulates phenotype, and distinct methylation pat-
terns have been associated with tissue specificity and a
variety of disease states ranging from cancer to neurological
disorders [5,6]. These tissue specific differentially methyl-
ated regions (tDMRs) are currently under investigation forral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nosis, particularly in the field of cancer research, disease de-
tection and response to treatment [7].
The discovery of cell free fetal DNA (cffDNA) in the
maternal circulation has greatly facilitated the develop-
ment of non-invasive prenatal diagnosis (NIPD) [8]. The
direct correlation between phenotype and DNA methy-
lation patterns has allowed the use of DMRs as possible
biomarkers in prenatal diagnosis. Several groups have
utilized the methylation differences between placenta-
derived cffDNA and maternal DNA in order to identify
highly specific fetal DMR biomarkers for non-invasive
prenatal diagnosis of aneuploidies. Previous studies
employed a variety of methods including sodium bisul-
fite conversion and methylation sensitive restriction di-
gestion, but yielded a relatively small number of fetal
specific DMRs including the SERPINB5, RASSF1A and
U-PDE9A genes [9-11].
In 2009, Papageorgiou et al. [12] applied methylation
DNA immunoprecipitation (MeDIP) coupled with high
resolution tiling oligonucleotide array (Chip) analysis to
identify DMRs between Chorionic villus sampling (CVS)
and female peripheral blood DNA (WBF). They were able
to identify thousands of DMRs on chromosomes 13, 18,
21, X, and Y including methylation sensitive restriction
sites, CGIs and promoter regions. This MeDIP-Chip ap-
proach was the trigger for investigating the utility of
MeDIP followed by real-time qPCR (MeDIP-qPCR) for
the non-invasive prenatal diagnosis of trisomy 21, yielding
100% sensitivity and specificity [13]. This novel NIPD
method was validated by a second study of 175 cases again
yielding high sensitivity and specificity [14].
The current study utilizes the MeDIP-qPCR method-
ology to expand our range of fetal specific DMR bio-
markers by selecting and screening 15 additional DMRs
on chromosomes 21 and 18. Special emphasis is given
on investigating the methylation variability in different
samples from these newly selected and previously reported
DMRs [12-14] by screening them in a set of 50, 1st trimes-
ter CVS and 50 WBF. Overall, this work confirms the dis-
tinctively different methylation status of these regions in
CVS and WBF.
Results
Using the above criteria we identified a set of 40 candi-
date DMRs between CVS and WBF from the microarray
data [12]. This set was subsequently screened in a cohort
of six CVS and six WBF to calculate the enrichment
values for each DMR (Additional file 1). Based on this
initial screening we were able to select the 15 regions
with the highest CVS enrichment for further validation/
characterization, using seven previously validated DMRs
by Papageorgiou et al. [13] and Tsaliki et al. [14], as a
comparison standard.This DMR validation study was conducted on a set of
50 CVS and 50 WBF samples using the MeDIP–qPCR
methodology (Table 1), the efficiency of which was mon-
itored using one hypermethylated (HYPER) and one hypo-
methylated (HYPO) control regions. The HYPER is a
region that showed hypermethylation for both CVS and
WBF, while the HYPO is a region that showed hypome-
thylation for the two tissues [12]. Enrichment values for
HYPO were low in WBF and CVS samples while the
HYPER control region showed enrichment for CVS and
WBF with mean enrichment values of 3.12 and 3.22 re-
spectively, indicating that the MeDIP procedure was
highly specific for the methylated regions. Moreover, the
previously validated DMRs performed as previously de-
scribed [12], exhibiting distinctively different enrichment
between CVS and WBF.
All tested DMRs showed a significant enrichment (p <
0.01) in CVS compared to those of WBF (Table 1). We
compared the performance of the 15 newly selected
DMRs with the previously validated set and we were able
to determine that 11 of 15 DMRs showed enrichment
values higher than the lowest of the previously validated
DMRs, ranging from 1.9 to 6.4. Additional comparison of
the two DMR sets also illustrated that for 11 of these 15
regions the difference of means (mean enrichment CVS –
mean enrichment WBF) was again higher than the re-
spective values of the validated DMRs (ranging from 1.6
to 6.4) (Table 1). Our analysis also shows that the enrich-
ment distributions for CVS and WBF have no overlap for
these 11 DMRs (Figure 1).
To better investigate tissue specificity (CVS-WBF) in
the 15 newly selected DMRs in relation to the previously
validated DMRs, we also constructed a heat map and
hierarchical clustering of the 50 CVS and 50 WBF sam-
ples based on the obtained enrichment values (Figure 2).
This analysis shows a clear differentiation between the
two tissue types based on the obtained enrichment
values. Furthermore, DMR clustering analysis showed
that there was no distinct clustering separation between
the newly selected and the previously validated DMRs.
Discussion
Our study aimed to validate and characterize a set of dif-
ferentially methylated regions between CVS and WBF, ob-
tained from MeDIP-Chip data [12]. The methylation
characteristics of the 15 candidate DMRs, located on chro-
mosomes 18 and 21, were ascertained in 50 CVS and 50
WBF using the MeDIP-qPCR methodology. To our know-
ledge this is the first MeDIP based biomarker screening
study utilizing such a large sample set. None of the se-
lected DMRs were located on CGIs, but within intergenic
or intragenic regions. Such DMR distribution in non-
coding intergenic and intragenic sequences is in agree-
ment with data from a large scale investigation of tissue
Table 1 Ranking of DMRs tested according to the difference between mean enrichment values for each DMRs
Marker Mean WBF Mean CVS Mean difference SD WBF SD CVS U pval Coefficient of variation WBF Coefficient of variation CVS
EI-4 0.017 6.384 6.367 0.022 2.143 1.53E-17 1.294 0.336
EII-1 0.065 5.319 5.254 0.071 1.937 7.06E-18 1.092 0.364
H2 0.135 4.068 3.933 0.093 1.252 7.06E-18 0.689 0.308
EI-2 0.064 3.894 3.83 0.2 1.338 7.50E-18 3.125 0.344
EI-3 0.116 3.905 3.789 0.312 1.556 1.96E-17 2.690 0.398
B3 0.126 3.86 3.734 0.1 1.268 2.29E-17 0.794 0.328
M27 0.532 4.113 3.581 0.2 1.386 7.06E-18 0.376 0.337
D2 0.317 3.364 3.047 0.179 1.301 7.06E-18 0.565 0.387
M28 0.189 2.777 2.588 0.125 0.919 7.06E-18 0.661 0.331
M1E 0.149 2.636 2.487 0.097 0.742 3.44E-17 0.651 0.281
Id1 0.398 2.682 2.284 0.155 0.932 1.04E-17 0.389 0.348
A5 0.337 2.505 2.168 0.159 0.986 7.06E-18 0.472 0.394
C5 0.18 2.321 2.141 0.106 0.84 7.06E-18 0.589 0.362
C1 0.106 2.229 2.123 0.083 0.635 7.06E-18 0.783 0.285
AII-2 0.065 2.003 1.938 0.084 0.933 1.23E-16 1.292 0.466
On2 0.281 1.993 1.712 0.138 0.552 7.06E-18 0.491 0.277
Nn2 0.245 1.924 1.679 0.107 0.78 7.07E-18 0.437 0.405
J2 0.116 1.707 1.591 0.079 0.519 7.06E-18 0.681 0.304
Fd1 0.135 1.676 1.541 0.101 0.513 7.06E-18 0.748 0.306
M25 1.038 1.822 0.784 0.452 0.655 1.88E-09 0.435 0.359
M20 0.42 0.796 0.376 0.186 0.303 2.37E-10 0.443 0.381
M18 0.097 0.22 0.123 0.07 0.151 6.36E-08 0.722 0.686
HYPER 3.124 3.226 0.102 0.68 0.982 0.951 0.218 0.304
HYPO 0.469 0.508 0.039 0.945 0.948 0.119 2.015 1.866
Despite the statistical significance of all enrichment values (p < 0.01), the four markers (M25, M20, M18, Fd1) that showed the lowest difference were not selected
as potential DMRs.
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ported differential methylation of intergenic and CpG
poor promoter regions in addition to CGIs.
Based on our results, all 15 DMRs showed differential
enrichment between the two tissues and 11 out of these
15 were strongly and consistently hypermethylated in
CVS samples. The ability of these DMRs to distinguish
between CVS and WBF was equivalent to that of the
seven previously validated DMRs used as performance
standards. In fact, the tissue discriminating performance
of the DMRs tested here, shows close similarities with
the previously validated DMRs as it is illustrated by our
heat map distribution and the unsupervised clustering
patterns obtained.
DMR enrichment values showed variability among the
different samples. This is likely caused by combination
of both inter-experimental technical variability and
inter-individual methylation variability. The presence of
variability in MeDIP based assays has previously been
described by Butcher et al. [16]. In addition, the issue of
inter-individual DNA methylation variability has beenthe focus of several studies [17-19]. This high inter-
individual variability has been attributed to a variety of
factors including environmental conditions, diet, age and
psychosocial factors [20-23]. Furthermore, it has been
documented that regions with low CpG density, as the
DMRs under investigation, show higher inter-individual
variability as compared to regions with high CpG dens-
ity, such as CGIs [24].
Others have also shown that methylation variability can
coincide with tissue specific DMRs without obscuring the
tissue discriminating properties of those DMRs [17]. It is
therefore of no surprise that despite the DNA methylation
variability in our study, the newly validated set of 11 DMRs
clearly distinguishes between CVS and WBF tissues.
Our work here substantially increases the number of
confirmed chromosome 21 fetal specific DMRs, and there-
fore provides a significant expansion in the biomarker
panel available for MeDIP-qPCR-based NIPD of Down
syndrome. Such an expansion is predicted to further im-
prove the robustness of the methodology and bolster its
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Figure 1 Enrichment profile for all DMRs on 50 WBF and 50 first trimester CVS. Box plots show the distribution of the relative fold
enrichment values for WBF (black) and CVS (red) for each DMR. The median value is represented by a horizontal line. The bottom of the box
indicates the 25th percentile (lower quartile) and the top the 75th percentile (upper quartile). Whisker lines indicate the outlier boundaries [top:
median + 3(75%-25%); bottom: median -3(75%-25%)]. A: 11 of 15 newly characterized DMRs show clear separation of the methylation enrichment
values between WBF and CVS despite the methylation variability. Fd1, M18, M20, M25 show overlap between the interquartile values, thus they
were not characterized as DMRs. B: Previously validated DMRs used as a comparison standard show clear separation between WBF and CVS.
HYPER: hypermethylated marker for both tissues, HYPO: Hypomethylated marker for both tissues.
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chromosome 18 fetal specific DMRs in a relatively large
sample set. This small panel of chromosome 18 DMRs
can potentially provide a very valuable testing platform
on which future NIPD assays for Edwards syndrome will
be developed.Conclusions
NIPD has gained a lot of interest the last few years. Util-
izing the methylation differences between fetal and
maternal DNA, several groups have managed to identify
biomarkers using different approaches. This study aimed
to characterize and validate fetal specific methylated re-
gions using the MeDIP-qPCR methodology. We were able
to show that the selected regions had distinct methylation
patterns between fetal and maternal tissue, despite inter-
individual and inter-experimental variability. In addition,
we have expanded the panel of the existing DMRs on
chromosome 21 and have characterized a new set of
markers on chromosome 18 which can provide the start-
ing point towards the development for assays towards the
detection of Edwards syndrome.Methods
Human Samples and DNA preparation
WBF samples were obtained anonymously from 50 nor-
mal non-pregnant females 20-40 years of age. Fifty, 1st tri-
mester CVS were obtained from the Department of
Cytogenetic and Genomics at the Cyprus Institute of
Neurology and Genetics (Nicosia, Cyprus). Protocols
used for collecting samples for our study were approved
by the appropriate Bioethics Committees, and informed
consent was obtained from all participants. WBF and
CVS samples were used to extract DNA using the
QIAamp DNA blood midi kit or the QIAmp DNA mini
kit according to the manufacturer’s instructions (QIA-
GEN, Hilden, Germany). All CVS underwent karyotyping
and Quantitative-Fluorescent PCR (QF-PCR) analysis in
order to confirm their normal status.
Ligation-mediated PCR (LM-PCR) and MeDIP assay
LM-PCR and MeDIP assays were conducted as de-
scribed previously [12]. Briefly, 2.5 μg of genomic DNA
were sonicated using the Bioruptor Twin sonication sys-
tem (UCD-400, Diagenode, Liege, Belgium) into frag-







































































































































































Figure 2 DMRs exhibiting tissue specificity between CVS and WBF. A heat map constructed based on the relative fold enrichment values
obtained for the two tissues tested (CVS and WBF) with the MeDIP-qPCR approach shows clustering of the hypermethylated CVS samples (high
enrichment-red) and the hypomethylated WBF samples (low enrichment–blue). Furthermore, DMR clustering analysis showed no cluster
distinction between the 15 newly selected DMRs and the previously validated DMRs that were used in this study as a comparison standard.
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blunt-ended using HPLC water, 1X NEB buffer 2 (New
England BioLabs, Ipswich, UK), 10X bovine serum albu-
min (New England BioLabs) 100 mmol/L dNTP mix
(GE Healthcare, Little Chalfont, UK) and T4 DNA poly-
merase (3 U/μl; New England BioLabs). Fragments were
purified using the QiAquick PCR purification kit (Qiagen)
and linkers were then ligated onto the blunt ends byovernight incubation at 16°C with T4 DNA ligase (New
England) and T4 DNA ligase buffer (New England). Over-
hangs were subsequently filled in by incubating at 72°C for
10 minutes with 100 mmol/L dNTP mix (GE Healthcare),
1X PCR gold buffer (Roche, Mannheim, Germany),
1.5 mmol/L MgCl2 (Roche) HPLC water and AmpliTaq
DNA polymerase (Applied Biosystems, Branchburg,
New Jersey, USA). 50 ng of ligated DNA was removed and
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1200 ng) was subjected to MeDIP using 3 μg mouse anti-
5’methylCytosine (a-5mC) antibody (Eurogentec Saraing,
Belgium). Hypermethylated DNA bound to a-mC anti-
bodies was magnetically captured using Dynabeads®
M-280 Sheep Anti-Mouse IgG magnetic beads (Life
technologies, Carlsbad, California, USA) and subse-
quently released using proteinase K (Roche). LM-PCR
used 12 ng of each input and MeDIP DNA as described
earlier [12].DMR selection
Candidate DMRs on chromosomes 18 and 21 were se-
lected from a set of potential differentially methylated
regions previously described [12] according to the fol-
lowing three criteria: a) the region included at least three
consecutive microarray probes, b) array results showed
consistent DNA hypermethylation in first and third tri-
mester placentas and hypomethylation in WBF samples,
c) the region did not include segmental duplications and
copy number variable regions based on the Database for
Genomic Variants (DGV) [25]. The regions considered
for this paper are shown in Table 2.Table 2 Characteristics of the regions tested






















Regions in bold indicate previously validated regions [13,14].Real-Time quantitative PCR (qPCR)
Primer design, optimal primer concentration experiments,
and efficiency (e) of each qPCR reaction were performed
as previously described [12] with the following modifi-
cations. Each qPCR reaction was performed on 8 ng of
template DNA using SYBR Green PCR mastermix
(Eurogentec) in a final reaction volume of 10 μl, using a
BIORAD CFX 384 Real time system (BIORAD, Hercules,
California). Each MeDIP, or Input template DNA was used
to prepare three replicate qPCR reactions that were used
for calculating the average Ct value for each template. Pri-
mer3 software [26] was used to design the qPCR primer
sets that were synthesized by Sigma-Aldrich (Munich,
Germany). Primer sets utilized for this body of work are
listed in Table 3.
Statistical calculations
MeDIP enrichment values of the CVS and WBF samples
were calculated for each region using the following
equation:
Enrichment = eΔCt where e corresponds to the effi-
ciency obtained in each real-time PCR reaction e = 10(-1/
slope of STD curve)) and ΔCt indicates the cycle difference be-






















Table 3 Primer sequences on DMRs tested
Primer Forward Reverse Position
CHR21(M27) ATACGTGTCCTGCCTTCCAC GCTTTGAGCAGAGAGGGAAA 42178812-42178948
CHR21(M28) CCCAGAAATTCCATTTGCAG GAAAGGCTCAACCAACCAAC 45171107-45171192
CHR21(M1E) TCGCACTGAGGCTTCCTACT AAGTTGTGGGCTGGGATTTT 44953674-44953772
CHR21(Nn2) ACCATTGTGGATCACAGCAG GCTCCGAGGATTAGGGAAAG 31427008-31427139
CHR21(On2) CTCCTGACCCACTCCCAATA GGAAACTCAGGGTCAAACGA 34492982-34493090
CHR21(Fd1) ATGTTGCCTGGGATATGCTT AACTGGCTGCGTGAGGATA 42006045-42006153
CHR21(EI-3) GCCTTGGGACAAAAATGACA TGGGCACAGCCCTAACTAAC 42355352-42355484
CHR21(EI-4) GGCCAGGTTGTTTCAGATTG TTCCGGCAGAGTTTATTTGG 42355802-42355908
CHR21(Id1) ACCGTATCATTTCCCCAGGT TGACCACATTTCCACCACAG 42753720-42753866
CHR21(A5) GCTGGACCAGAAAGTGTTGAG GTGTGCTGCTTTGCAATGTG 39279856-39280004
CHR21(C5) CTGTTGCATGAGAGCAGAGG CGTCCCCCTCGCTACTATCT 33320735-33320829
CHR21(D2) TGCAGGATATTTGGCAAGGT CTGTGCCGGTAGAAATGGTT 42189557-42189683
CHR21(EI-2) TGAATCAGTTCACCGACAGC GAAACAACCTGGCCATTCTC 42355712-42355815
CHR21(EII-1) CCGTTATATGGATGCCTTGG AAACTGTTGGGCTGAACTGC 42357215-42357341
CHR21(H2) CCACATCCTGGCCATCTACT TTCCACAGACAGCAGAGACG 32268843-32268943
CHR21(M18) GATGGATGGCCTTTTGGTAA TATTTGGTTTGCCCCTTCCT 15331818-5331945
CHR21(M20) CATTAGCGGGTCAGCTAGGA TGGCAATTACATCTGCCATTA 15178413-5178497
CHR21(M25) TTGTCTGCCCGTATGGAAGT ATGGTTGTAGGGCTCATTCA 37692864-37692974
CHR21(J2) ATTCTCCACAGGGCAATGAG TTATGTGGCCTTTCCTCCTG 37841284-37841411
CHR18(AII2) TGTGCCTCTCCCTTGAGACT AAATTGCAGCCAATGCTTCT 55090427-55090524
CHR18(B3) TGTGGTTTCAAACATGCACA CTGAAAAGGCCACTCTGAGG 44166131-44166263
CHR18(C1) GTGAGAGAGAACGCCAGGAG TGAGCCAACTCTGGTGTCAG 58956266-58956391
HYPER CAGGAAAGTGAAGGGAGCTG CAAAACCCAATGGTCAATCC 19991387-19991465
HYPO AGGTGCCCAATTCAAGGTA CTTCCCCACCAGTCTTGAAA 30214952-30215055
Regions in bold indicate previously validated regions [13,14].
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http://www.molecularcytogenetics.org/content/7/1/73The mean enrichment values of each DMR were com-
pared between WBF and CVS samples using the Mann-
Whitney U tests [27] and the corresponding p-values
were used to decide whether there was significant evi-
dence to claim that the mean enrichments of the two
groups were different.
Hierarchical clustering of the DMRs was conducted
using an iterative algorithm that joins similar clusters
based on the set of dissimilarities of the 100 individuals
(calculating the Euclidean distanced between clusters)
and re-computing their distances at each stage by the
Lance-Williams dissimilarity update formula [28].
Additional file
Additional file 1: Initial screening on six WBF and six CVS for the
selection of new DMRs.
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